



- (51) **International Patent Classification:**
G01N 33/68 (2006.01)
- (21) **International Application Number:**
PCT/US2021/017217
- (22) **International Filing Date:**
09 February 2021 (09.02.2021)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
62/972,418 10 February 2020 (10.02.2020) US
- (71) **Applicant: SOMALOGIC, INC.** [US/US]; 2945 Wilderness Place, Boulder, Colorado 80301 (US).
- (72) **Inventors: ALEXANDER, Leigh;** c/o SomaLogic, Inc., 2945 Wilderness Place, Boulder, Colorado 80301 (US). **OSTROFF, Rachel;** c/o SomaLogic, Inc., 2945 Wilderness Place, Boulder, Colorado 80301 (US). **FIELD, Stuart;** c/o SomaLogic, Inc., 2945 Wilderness Place, Boulder, Colorado 80301 (US).
- (74) **Agent: SCARR, Rebecca et al.;** McNeill Baur PLLC, 125 Cambridge Park Drive, Suite 301, Cambridge, Massachusetts 02140 (US).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

- (54) **Title:** NONALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKERS AND USES THEREOF




Fig. 1

- (57) **Abstract:** Methods, compositions, and kits for determining whether a subject has a liver condition, including hepatic steatosis, hepatic inflammation, hepatocellular ballooning, and/or hepatic fibrosis, are provided. In various embodiments, the subject's liver condition includes non-alcoholic steatohepatitis (NASH).

